<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="15044">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02024308</url>
  </required_header>
  <id_info>
    <org_study_id>CHXY-AML01</org_study_id>
    <nct_id>NCT02024308</nct_id>
  </id_info>
  <brief_title>AML1-ETO Acute Myeloid Leukemia With Fludarabine and Cytarabine Chemotherapy</brief_title>
  <official_title>A Randomized Comparison of Fludarabine in Combination With Cytarabine Versus High -Dose Cytarabine in Post-remission Therapy for AML1-ETO Acute Myeloid Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Changhai Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Changhai Hospital</source>
  <oversight_info>
    <authority>China: Ethics Committee</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine whether Fludarabine in  combination with cytarabine
      is more effective than high-dose cytarabine in post-remission therapy for patients with
      AML1-ETO acute myeloid leukemia.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2010</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">November 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Percentage of participants with disease recurrence</measure>
    <time_frame>one year</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants in survival</measure>
    <time_frame>one year</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">62</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <condition>AML1-ETO Fusion Protein Expression</condition>
  <arm_group>
    <arm_group_label>Fludarabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The patients in experimental arm should receive the consolidation chemotherapy regimen with fludarabine and cytarabine. The dosage of fludarabine is 30mg/m2/d for 5 days intravenously and cytarabine is 1.4g/m2/d for 5 days intravenously.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HD-Arac</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The patients in control arm should receive the consolidation chemotherapy regimen with high-dose cytarabine. The dosage of cytarabine is 2000mg/m2/12h for 3 days (1,3,5) intravenously.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>50 mg/m2, IV (in the vein) in combination with cytarabine 1.4mg/m2/d for 5 days with each cycle of 28 days. Number of cycles: 4</description>
    <arm_group_label>Fludarabine</arm_group_label>
    <other_name>Fludara</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytarabine</intervention_name>
    <description>2000mg/m2/12h, IV (in the vein) for 3 days with each cycle of 28 days. Number of cycles: 4</description>
    <arm_group_label>Fludarabine</arm_group_label>
    <arm_group_label>HD-Arac</arm_group_label>
    <other_name>Cytosar</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical and laboratory diagnosis of AML1-ETO positive acute myeloid leukemia

          -  In status of complete remission after one to two courses of induction therapy with
             DA(Daunorubicin 60mg/m2/d for 3 days, cytarabine 100mg/m2/d for 5-7days) regimen

          -  ECOG (Eastern Cooperative Oncology Group)  score: &lt;2

        Exclusion Criteria:

          -  Serious liver/ kidney dysfunction

          -  Cardiac function level: 2 above

          -  Female in  pregnancy or lactation

          -  With serious infection diseases or other diseases
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xianmin Song, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Hematology, Changhai Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xianmin Song, Doctor</last_name>
    <phone>83-21-31161285</phone>
    <email>shongxm@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Hematology, Changhai Hospital</name>
      <address>
        <city>Shanghai</city>
        <zip>200433</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xianmin Song</last_name>
      <phone>86-21-31161285</phone>
      <email>shongxm@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Xianmin Song</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 27, 2013</lastchanged_date>
  <firstreceived_date>December 20, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Changhai Hospital</investigator_affiliation>
    <investigator_full_name>Xianmin Song</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>acute myeloid leukemia,</keyword>
  <keyword>AML1-ETO fusion protein,</keyword>
  <keyword>Fludarabine,</keyword>
  <keyword>recurrence</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Fludarabine monophosphate</mesh_term>
    <mesh_term>Vidarabine</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
